Homology Medicines, Inc. — Form D/A
Homology Medicines, Inc. of BEDFORD, MA, a company, filed a Form D amendment with the SEC on 2017-02-16. The offering totals $43.6M, of which $43.6M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2017-02-16
- Form: D/A
- Accession: 0001661998-17-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $43.6M
- Amount sold: $43.6M
- Investors: 7
- Date of first sale: 2015-12-22
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-254611
Issuer
- Name: Homology Medicines, Inc.
- CIK: 0001661998
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 45 WIGGINS AVE., BEDFORD, MA, 01730
- Phone: 781-301-7277
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Steven Gillis | Director | South San Francisco, CA |
| Mahendra Shah | Director | Palo Alto, CA |
| Brad Smith | Executive Officer | CAMBRIDGE, MA |
| Cameron Wheeler | Director | Cambridge, MA |
| Richard Gregory | Director | Toronto, A6 |
| Kush Parmar | Director | San Francisco, CA |
| Kush Parmar | Executive Officer | San Francisco, CA |
| Albert Seymour | Executive Officer | Boston, MA |
| Paul Stone | Director | Portland, OR |
| Paul Stone | Executive Officer | Portland, OR |
| Arthur Tzianabos | Director | Boston, MA |
| Arthur Tzianabos | Executive Officer | Boston, MA |
| Siyamak Rasty | Executive Officer | Bedford, MA |
Other filings by this issuer (2)
More